螺旋断层放疗治疗头颈部肿瘤的初步临床经验。
Initial clinical experience with helical tomotherapy for head and neck cancer.
机构信息
Department of Radiation Oncology, University of California Davis School of Medicine, Sacramento, California 95817, USA.
出版信息
Head Neck. 2009 Dec;31(12):1571-8. doi: 10.1002/hed.21123.
BACKGROUND
To report a single-institutional experience with the use of helical tomotherapy (HT)-based intensity-modulated radiotherapy (IMRT) for head and neck cancer.
METHODS
Seventy-seven consecutive patients were treated with HT for squamous cell carcinoma of the head and neck to a median dose of 66 Gy (range, 60 to 72 Gy). Megavoltage CT scans were obtained as part of an image-guided registration protocol for patient alignment before each treatment. Concurrent chemotherapy was administered to 48 patients (62%).
RESULTS
The 2-year estimates of overall survival, local-regional control, and disease-free survival were 82%, 77%, and 71%, respectively. Spatial evaluation of local-regional failures revealed that 16 of the 18 patients who progressed in the primary site or neck failed in the high-dose planning target volume (PTV).
CONCLUSIONS
HT appears to achieve clinical outcomes comparable to contemporary series reporting on IMRT for head and neck cancer.
背景
报告了单机构使用螺旋断层放疗（HT）的强度调制放疗（IMRT）治疗头颈部癌症的经验。
方法
77 例连续的头颈部鳞状细胞癌患者接受 HT 治疗，中位剂量为 66 Gy（范围 60 至 72 Gy）。在每次治疗前，作为图像引导注册协议的一部分，进行兆伏 CT 扫描以进行患者对准。48 例患者（62%）接受了同期化疗。
结果
2 年的总生存率、局部区域控制率和无病生存率分别为 82%、77%和 71%。局部区域失败的空间评估显示，18 例原发灶或颈部进展的患者中有 16 例在高剂量计划靶区（PTV）失败。
结论
HT 似乎可以达到与报告头颈部癌症 IMRT 的当代系列相当的临床结果。
Zotero 插件